Medicare Enrolled
Dr. Radhika Rajsheker, MD
Hematology & Oncology · Middletown, OH
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rajsheker from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rajsheker?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rajsheker
Dr. Radhika Rajsheker is a hematology & oncology specialist in Middletown, OH, with 18 years of NPI registration. Based on federal Medicare data, Dr. Rajsheker performed 59,244 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Rajsheker received a total of $10,929 from 77 pharmaceutical and/or device companies across 609 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rajsheker is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years of NPI registration
▲ Top 7% volume in OH
$10,929 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗59,244
Medicare services
Top 7% in OH for hematology & oncology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
24,601 | $0 | $0 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
12,900 | $0 | $1 |
| Pembrolizumab injection (Keytruda) | 10,200 | $42 | $99 |
| Paclitaxel chemotherapy injection | 3,120 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,694 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 1,560 | $18 | $37 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,170 | $1 | $3 |
| Injection, leucovorin calcium, per 50 mg | 581 | $3 | $11 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
518 | $59 | $140 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
373 | $2 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
371 | $90 | $207 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
264 | $11 | $64 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
218 | $94 | $403 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
195 | $46 | $181 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
164 | $89 | $156 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
120 | $21 | $100 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
113 | $10 | $45 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
104 | $2 | $6 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
81 | $7 | $50 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
80 | $1 | $1 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
79 | $21 | $92 |
| Anti-nausea injection (ondansetron/Zofran) | 70 | $0 | $0 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
62 | $58 | $110 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
59 | $46 | $198 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
58 | $53 | $155 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
55 | $41 | $166 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
55 | $132 | $281 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
46 | $2 | $5 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
41 | $9 | $37 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
38 | $129 | $313 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
36 | $27 | $135 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
36 | $121 | $399 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
35 | $1 | $4 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
28 | $116 | $320 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
27 | $23 | $148 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
25 | $209 | $448 |
| New patient office visit, complex (60-74 min) | 20 | $158 | $402 |
| Transitional care management services, moderate complexity Services provided to coordinate care during the transition from an inpatient or other facility setting back to the community. This includes follow-up and management of a health problem of at least moderate complexity. |
17 | $154 | $318 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
16 | $14 | $66 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
14 | $51 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.1% high complexity
96.6% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,929
Total received (2018-2024)
Avg $1,561/year across 7 years
Top 27% in OH for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
609
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,130
2023
$3,128
2022
$1,275
2021
$458
2020
$379
2019
$1,603
2018
$956
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$283
ABBVIE INC.
$259
Incyte Corporation
$187
PFIZER INC.
$180
Merck Sharp & Dohme LLC
$170
Janssen Biotech, Inc.
$154
Medical Device Business Services, Inc.
$152
Daiichi Sankyo Inc.
$135
AstraZeneca Pharmaceuticals LP
$134
Lilly USA, LLC
$115
Genentech USA, Inc.
$106
Gilead Sciences, Inc.
$83
GlaxoSmithKline, LLC.
$78
Rigel Pharmaceuticals, Inc.
$77
Celgene Corporation
$66
SOBI, INC
$65
Regeneron Healthcare Solutions, Inc.
$64
TerSera Therapeutics LLC
$64
E.R. Squibb & Sons, L.L.C.
$57
PharmaEssentia USA Corporation
$54
Bayer Healthcare Pharmaceuticals Inc.
$53
Cardinal Health 110 LLC
$49
Genmab U.S., Inc.
$46
GENZYME CORPORATION
$44
Eisai Inc.
$44
Astellas Pharma US Inc
$42
BeiGene USA, Inc.
$42
SERVIER PHARMACEUTICALS LLC
$41
Aveo Pharmaceuticals, Inc.
$39
Stemline Therapeutics Inc.
$37
Kyowa Kirin, Inc.
$33
TAIHO ONCOLOGY, INC.
$32
JAZZ PHARMACEUTICALS INC.
$31
Pharmacosmos Therapeutics Inc.
$31
Takeda Pharmaceuticals U.S.A., Inc.
$27
Alexion Pharmaceuticals, Inc.
$19
Adaptive Biotechnologies Corporation
$16
Agios Pharmaceuticals, Inc.
$15
Janssen Pharmaceuticals, Inc
$8
Top 3 companies account for 23.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,005
E.R. Squibb & Sons, L.L.C.
$597
Merck Sharp & Dohme LLC
$578
Janssen Biotech, Inc.
$525
PFIZER INC.
$473
AstraZeneca Pharmaceuticals LP
$414
Pharmacyclics LLC, An AbbVie Company
$390
Incyte Corporation
$350
Genentech USA, Inc.
$329
Lilly USA, LLC
$312
Daiichi Sankyo Inc.
$308
Exelixis Inc.
$293
GENZYME CORPORATION
$289
ABBVIE INC.
$288
Amgen Inc.
$273
EISAI INC.
$248
Eisai Inc.
$208
Gilead Sciences, Inc.
$198
Boehringer Ingelheim Pharmaceuticals, Inc.
$195
Celgene Corporation
$182
Regeneron Healthcare Solutions, Inc.
$177
Medical Device Business Services, Inc.
$152
TerSera Therapeutics LLC
$151
GlaxoSmithKline, LLC.
$143
Takeda Pharmaceuticals U.S.A., Inc.
$131
Bayer Healthcare Pharmaceuticals Inc.
$124
Janssen Pharmaceuticals, Inc
$122
Bayer HealthCare Pharmaceuticals Inc.
$114
Astellas Pharma US Inc
$113
ARRAY BIOPHARMA INC
$110
Pharmacyclics LLC, an AbbVie Company
$104
Rigel Pharmaceuticals, Inc.
$102
SANOFI-AVENTIS U.S. LLC
$99
Foundation Medicine, Inc.
$92
BeiGene USA, Inc.
$84
Kyowa Kirin, Inc.
$84
SOBI, INC
$81
Ipsen Biopharmaceuticals, Inc
$77
Genmab U.S., Inc.
$76
EMD Serono, Inc.
$75
Merck Sharp & Dohme Corporation
$72
Clovis Oncology, Inc.
$70
Seagen Inc.
$68
JAZZ PHARMACEUTICALS INC.
$59
Stemline Therapeutics Inc.
$58
SERVIER PHARMACEUTICALS LLC
$56
ADC Therapeutics America, Inc.
$56
PharmaEssentia USA Corporation
$54
TESARO, Inc.
$50
TAIHO ONCOLOGY, INC.
$50
Cardinal Health 110 LLC
$49
Janssen Scientific Affairs, LLC
$48
Adaptive Biotechnologies Corporation
$48
Kite Pharma, Inc.
$46
MorphoSys, US Inc.
$41
Aveo Pharmaceuticals, Inc.
$39
Lexicon Pharmaceuticals, Inc.
$37
Pharmacosmos Therapeutics Inc.
$31
Teva Pharmaceuticals USA, Inc.
$31
PUMA BIOTECHNOLOGY, INC.
$30
Seattle Genetics, Inc.
$24
Sun Pharmaceutical Industries Inc.
$22
Alexion Pharmaceuticals, Inc.
$19
Heron Therapeutics, Inc.
$18
Blueprint Medicines Corporation
$17
CTI BioPharma Corp.
$16
Alnylam Pharmaceuticals Inc.
$16
Agios Pharmaceuticals, Inc.
$15
AVEO Pharmaceuticals, Inc.
$14
Puma Biotechnology, Inc.
$14
Array BioPharma Inc.
$14
Myriad Genetic Laboratories, Inc.
$14
Mylan Institutional Inc.
$14
Sumitomo Pharma America, Inc.
$13
Karyopharm Therapeutics Inc.
$13
Deciphera Pharmaceuticals Inc.
$13
AbbVie Inc.
$13
Top 3 companies account for 19.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · ASPARLAS · AYVAKIT · Alecensa · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARTO 3 · CINVANTI · CYRAMZA · Cabometyx · Columvi · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FARESTON · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Perjeta · Phesgo · Polivy · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · Rezlidhia · Rubraca · SANDOSTATIN · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNAGIS · Stivarga · TASIGNA · TECVAYLI · TEPMETKO · TUKYSA · Tavalisse · Tazverik · Tecentriq · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex · clonoSEQ · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
53
County median income
$107,843
Nearest hospital to ZIP centroid (approximate)
ATRIUM MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rajsheker is a mixed practice specialist, with above-average Medicare volume (top 7% in OH), with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rajsheker experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Rajsheker performed 24,601 iron sucrose injection (venofer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Rajsheker receive payments from pharmaceutical companies?
Yes. Dr. Rajsheker received a total of $10,929 from 77 companies across 609 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rajsheker's costs compare to other hematology & oncology specialists in Middletown?
Dr. Rajsheker's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rajsheker) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Middletown
Browse hematology & oncology specialists in Middletown ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in OH
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in OH
Which OH hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology